Sino Biopharmaceutical signs cancer deal worth up to $7 billion with Boehringer Ingelheim
Sino Biopharmaceutical entered an option and license agreement with Germany's Boehringer Ingelheim for six pre-clinical oncology programs that could generate up to approximately $7 billion in total value.
